Document Detail

Angiotensin-converting enzyme (ACE) dimerization is the initial step in the ACE inhibitor-induced ACE signaling cascade in endothelial cells.
MedLine Citation:
PMID:  16476786     Owner:  NLM     Status:  MEDLINE    
The binding of angiotensin-converting enzyme (ACE) inhibitors to ACE initiates a signaling cascade that involves the phosphorylation of the enzyme on Ser1270 as well as activation of the c-Jun NH2-terminal kinase (JNK) and leads to alterations in gene expression. To clarify how ACE inhibitors activate this pathway, we determined their effect on the ability of the enzyme to dimerize and the role of ACE dimerization in the initiation of the ACE signaling cascade. In endothelial cells, ACE was detected as a monomer as well as a dimer in native gel electrophoresis and dimerization/oligomerization was confirmed using the split-ubiquitin assay in yeast. ACE inhibitors elicited a rapid, concentration-dependent increase in the dimer/monomer ratio that correlated with that of the ACE inhibitorinduced phosphorylation of ACE. Cell treatment with galactose and glucose to prevent the putative lectin-mediated self-association of ACE or with specific antibodies shielding the N terminus of ACE failed to affect either the basal or the ACE inhibitor-induced dimerization of the enzyme. In ACE-expressing Chinese hamster ovary cells, ACE inhibitors elicited ACE dimerization and phosphorylation as well as the activation of JNK with similar kinetics to those observed in endothelial cells. However, these effects were prevented by the mutation of the essential Zn2+-complexing histidines in the C-terminal active site of the enzyme. Mutation of the N-terminal active site of ACE was without effect. Together, our data suggest that ACE inhibitors can initiate the ACE signaling pathway by inducing ACE dimerization, most probably via the C-terminal active site of the enzyme.
Karin Kohlstedt; Cynthia Gershome; Matthias Friedrich; Werner Müller-Esterl; François Alhenc-Gelas; Rudi Busse; Ingrid Fleming
Related Documents :
7702566 - Adenylate cyclase, cyclic amp and extracellular-signal-regulated kinase-2 in airway smo...
2441696 - Acidic heparin binding growth factor transiently activates adenylate cyclase activity i...
18426886 - Suppression of t-lymphocyte activation and chemotaxis by the adenylate cyclase toxin of...
6298116 - Guanine nucleotide mediated desensitization of adenylate cyclase in cell free preparati...
3489816 - (6r)-tetrahydrobiopterin increases the activity of tryptophan hydroxylase in rat raphe ...
23695676 - Pi 3-kinase-dependent phosphorylation of plk1-ser99 promotes association with 14-3-3γ ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2006-02-13
Journal Detail:
Title:  Molecular pharmacology     Volume:  69     ISSN:  0026-895X     ISO Abbreviation:  Mol. Pharmacol.     Publication Date:  2006 May 
Date Detail:
Created Date:  2006-04-18     Completed Date:  2006-06-26     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0035623     Medline TA:  Mol Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1725-32     Citation Subset:  IM    
Vascular Signalling Group, Institut für Kardiovaskuläre Physiologie, Johann Wolfgang Goethe-Universität, Theodor-Stern-Kai 7, D-60590 Frankfurt am Main, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Androstadienes / pharmacology
Angiotensin-Converting Enzyme Inhibitors / pharmacology*
Chromones / pharmacology
Endothelium, Vascular / drug effects,  enzymology,  physiology*
Enzyme Inhibitors / pharmacology
Lipopolysaccharides / pharmacology
Morpholines / pharmacology
Peptidyl-Dipeptidase A / metabolism*
Umbilical Veins
Reg. No./Substance:
0/Androstadienes; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Chromones; 0/Enzyme Inhibitors; 0/Lipopolysaccharides; 0/Morpholines; 154447-36-6/2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; 19545-26-7/wortmannin; EC A

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  No nitric oxide for HO-1 from sodium nitroprusside.
Next Document:  Natural resistance, iron and infection: a challenge for clinical medicine.